Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia

American Journal of Health-System Pharmacy

Volumn 68, Issue 7, 2011, Pages 590-598

  Kalra, Sanjay ^a   Efrati, Shai ^b   Arthur, John M ^c   Oliven, Arie ^d   Velez, Juan Carlos Q ^e   McNutt, Bruce E ^f   Klasen, Sally ^f   Abeyratne, Anura ^f  

^a India   (India)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d BNAI ZION MEDICAL CENTER   (Israel)

^e Children's Hospital of Michigan   (United States)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Conivaptan hydrochloride; Dosage; Drug administration; Formulations; Hyponatremia; Toxicity; Vasopressin antagonists

Indexed keywords

CONIVAPTAN; PLACEBO; SODIUM;

ADULT; AGED; AMPOULE; ANEMIA; ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EUVOLEMIC HYPONATREMIA; FEMALE; HUMAN; HYPERVOLEMIC HYPONATREMIA; HYPOKALEMIA; HYPONATREMIA; INCIDENCE; INJECTION SITE CELLULITIS; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INJECTION SITE WARMTH; LEUKOCYTOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SODIUM BLOOD LEVEL;

EID: 79956030128     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100243     Document Type: Article

References (24)

1. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001; 51:391-402. (Pubitemid 32718587)
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006; 119(suppl 1):S30-5.
3. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007; 120(suppl 1):S1-21.
4. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006; 119(suppl 1):S36-42.
5. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am. 2001; 30:671-94. (Pubitemid 32852809)
6. 2 receptor antagonists. J Mol Endocrinol. 2002; 29:1-9.
7. Anderson RJ, Chung HM, Kluge R et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985; 102:164-8. (Pubitemid 15157162)
8. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967; 42:790-806.
9. Schwartz WB, Bennett W, Curelop S et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957; 23:529-42.
10. Chen S, Jalandhara N, Batlle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract Nephrol. 2007; 3:82-95. (Pubitemid 46161000)
11. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol. 1986; 58:295-9. (Pubitemid 16052721)
12. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003; 32:459-81. (Pubitemid 36666228)
13. 2 receptor antagonist in dogs. Eur J Pharmacol. 1997; 321:225-30.
14. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997; 282:301-8.
15. 2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006; 91:2145-52.
16. Zeltser D, Rosansky S, van Rensburg H et al., for the Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007; 27:447-57. (Pubitemid 47482001)
17. Annane D, Decaux G, Smith N, for the Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009; 337:28-36.
18. Verbalis JG, Zeltser D, Smith N et al. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol. 2008; 69:159-68. (Pubitemid 351847263)
19. Vaprisol (conivaptan hydrochloride injection) package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2008.
20. Verbalis JG, Rosansky S, Wagoner LE et al. Conivaptan for the treatment of hyponatremia in hospitalized patients: results from an open-label study. Crit Care Med. 2006; 34(suppl):A64. Abstract.
21. Infusion Nurses Society. Infusion nursing standards of practice. J Infus Nurs. 2006; 29(suppl):S1-92.
22. Kraft MD, Btaiche IF, Sacks GS et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health-Syst Pharm. 2005; 62:1663-82. (Pubitemid 41153661)
23. Ellis SJ. Severe hyponatremia: complications and treatment. QJM. 1995; 88:905-9.
24. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342:1581-9. (Pubitemid 30340505)